ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Assessing the significance of CCNE1 overexpression in triple negative breast cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCyclin E1 (CCNE1), a critical regulator of cell cycle progression, has been implicated in various cancers; however, its prognostic significance and functional role across breast cancer (BC) subtypes remain inadequately defined. This study aims to comprehensively analyze CCNE1 mRNA expression and evaluate its potential as both a prognostic biomarker and a therapeutic guide.
methodsWe analyzed CCNE1 mRNA expression using large-scale BC cohorts (TCGA, METABRIC, GEO) and assessed associations with tumour grade, overall survival, and mutation status. The muTarget platform was employed to investigate associations between CCNE1 expression and key genetic alterations. Furthermore, gene set enrichment analysis was performed to identify enriched biological pathways, and functional studies were conducted using mTORC1 inhibition in TP53-mutant, RB1-deficient TNBC cells to evaluate cell viability and CCNE1 expression levels.
resultsCCNE1 expression was significantly associated with higher tumour grade, overall survival, and distinct mutation statuses. Gene set enrichment analysis revealed enrichment of proliferation-related pathways, including G2-M checkpoint, E2F targets, and mTORC1 signaling in CCNE1-high tumors. Moreover, functional studies showed that mTORC1 inhibition successfully reduced CCNE1 expression and impaired viability in TP53-mutant, RB1-deficient TNBC cells.
conclusionsCCNE1 overexpression characterises a clinically aggressive subset of breast cancers, particularly TNBC. Targeting mTORC1 may represent a promising therapeutic approach in CCNE1-high, TP53-mutated, and RB1-deficient tumours, supporting the clinical utility of CCNE1 in patient stratification and targeted therapy.
Indexed as
Identifiers
42517982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.